ReviewWorld journal of microbiology & biotechnology2025
Updates on therapeutic targeting of diguanylate cyclase for addressing bacterial infections: A comprehensive review.
Review in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antibiotic Resistance and the Return to a Pre-Antibiotic Era: A Critical Narrative Review of a Global Catastrophe.Biomedicines · 2026Review
- An IgM monoclonal antibody targeting diguanylate cyclase DgcE potentiates gentamicin activity against avian pathogenic Escherichia coli through modulation of c-di-GMP signaling.BMC veterinary research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The current global health issue of antimicrobial resistance necessitates innovative strategies for treating bacterial infections. A promising novel therapeutic target is the multisubunit diguanylate cyclase (DGC), which synthesizes cyclic di-GMP (c-di-GMP) and is implicated in biofilm formation. This multisubunit enzyme regulates critical virulence-associated behaviors in bacteria, such as biofilm formation, motility, and virulence factor synthesis, which are critical for biopathogenicity. This review focuses on the structural and functional characterization of DGCs, their contributions to bacterial pathogenesis, and recent advances in therapies targeting these enzymes. We describe innovations in small-molecule (SM) and peptide-based therapeutics and novel drug delivery platforms that alter DGC activity. In addition, we discuss new findings regarding DGCs and combination therapies of DGC inhibitors with other antibiotics. Finally, we outline the problems and prospects of therapies targeted to DGCs in the clinic. Inhibitors of DGCs may benefit from recent advances in structural biology techniques and medicinal chemistry approaches, which present new drug development opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.